The contemporary management of well-differentiated
thyroid cancer requires a multidisciplinary approach involving primary care
physicians, endocrinologists, surgeons, pathologists, nuclear medicine
specialists, and sometimes radiologists and oncologists for diagnosis,
treatment, and long-term surveillance. Well-differentiated thyroid carcinoma
includes papillary and follicular thyroid carcinomas. These two types of cancer
comprise approximately 85% to 90% of all thyroid malignancies. Managing these
cancers raises common concerns that will be addressed later.
Despite the fact that most cases of well-differentiated thyroid carcinoma
have an excellent prognosis, optimal treatment of the disease remains
controversial. Perhaps because of the slow growth of the tumors and the
infrequency with which patients die of the disease, no studies have been large
enough or of long-enough duration to definitively answer some of the central
questions in the treatment of well-differentiated thyroid cancer. The optimal
extent of surgical resection continues to be debated, as does the question of
which patients should receive radioactive iodine. Various authors have
questioned whether a lymph node dissection is beneficial to patients, and if so,
how extensive such a dissection should be.
Regardless of the answer to these questions, most patients with
well-differentiated thyroid cancer will do well, but only a large study with
several decades of follow-up will be able to discern any advantages among the
treatment options presented above. To date, there have been no randomized
studies to evaluate the comparative benefits of various treatment modalities.
Most patients with well-differentiated thyroid cancer initially present with
a thyroid nodule. The role of the primary care physician is critical at this
stage, because the majority of patients are diagnosed only after a nodule is
palpable on physical examination. Nevertheless, the increasing use of diagnostic
imaging such as carotid duplex scanning and computed tomography (CT) scanning
(for other reasons) has led to more frequent identification of thyroid nodules
before they are palpable.
Once a nodule is identified, the appropriate diagnostic work-up includes a
careful history with attention to risk factors such as radiation exposure,
previous thyroid cancer, or less commonly, family history of well-differentiated
thyroid cancer. Hoarseness or lymphadenopathy associated with a palpable
thyroid mass is particularly suspicious for carcinoma.
Numerous imaging modalities are available for evaluating thyroid nodules. In
most instances, an ultrasound of the neck will provide accurate and detailed
information about the nodule as well as the status of the remainder of the
thyroid, including any possible lymphadenopathy in the cervical region.
Increasingly, microcalcifications in association with a thyroid nodule have been
identified as suspicious for papillary thyroid carcinoma.
Thyroid scintigraphy continues to be helpful if the functionality of a nodule
is being questioned. CT scanning and magnetic resonance imaging (MRI) are
generally less helpful in the initial evaluation. Positron-emission tomography
(PET) scanning in conjunction with fluorine-18 fluorodeoxyglucose (FDG) has
shown promise in identifying thyroid malignancies, but it is not yet clear what
the most appropriate role for this imaging modality will be.[4,5]
A diagnosis of well-differentiated thyroid cancer is often made
preoperatively with the use of fine-needle aspiration (FNA) cytology. A
diagnosis of papillary thyroid carcinoma is readily made on cytologic
evaluation. The cells characteristically have enlarged nuclei with dense
chromatin and, frequently, intranuclear cytoplasmic inclusions.
The cytologic diagnosis of follicular thyroid carcinoma is more problematic.
The distinction between benign adenoma and malignant carcinoma for this type of
tumor is not based primarily on cellular features, but rather, on the presence
of capsular or vascular invasion. In other words, the cells in a benign
follicular adenoma and a malignant follicular carcinoma may be identical. The
distinction between benign and malignant depends largely on where the cells are
located. If there is no capsular or vascular invasion, then the lesion is
The nature of this distinction often leads to an indeterminate cytologic
evaluation, even when a follicular thyroid carcinoma has been aspirated. Such
nodules are usually characterized as "follicular neoplasms," since
benign lesions cannot be distinguished from malignant lesions on the basis of
cytology alone. When the results of the aspiration are indefinite, and because
the issue of capsular or vascular invasion cannot be determined no matter how
many times the cells in a nodule are sampled, most physicians recommend at least
a partial thyroidectomy (lobectomy or hemithyroidectomy). Only after the
pathologist has completely evaluated the entire nodule for capsular and vascular
invasion can such a tumor be categorized as a benign follicular adenoma.
Hürthle Cell Neoplasm
Follicular neoplasms can be further subcategorized into Hürthle cell
neoplasms. These uncommon tumors consist of large acidophilic or oncocytic
cells. Some authors have suggested that Hürthle cell carcinomas have a worse
prognosis than the usual follicular carcinoma.[7,8] This finding may be related
to the greater likelihood that Hürthle cell carcinomas are locally invasive and
concentrate radioiodine less avidly.
1. Mazzaferri EL: Thyroid cancer, in Becker KL (ed): Principles and Practice
of Endocrinology and Metabolism, 2nd ed, pp 454-366. Philadelphia, Lippincott,
2. Ozaki O, Ito K, Kobayashi K, et al: Familial occurrence of differentiated,
nonmedullary thyroid cancer. World J Surg 12:565-571, 1988.
3. Lu C, Chang TC, Hsiao YL, et al: Ultrasonographic findings of papillary
thyroid carcinoma and their relation to pathologic changes. J Formos Med Assoc
4. Schluter B, Grimm-Riepe C, Beyer W, et al: Histologic verification of
positive fluorine-18-fluorodeoxyglucose findings in patients with differentiated
thyroid cancer. Lagenbecks Arch Surg 383:187-189, 1998.
5. Uematsu H, Sadato N, Ohtsubo T, et al: Fluorine-18-fluorodeoxyglucose PET
vs thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med
6. Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med
7. Samaan NA, Schultz PN, Haynie TP, et al: Pulmonary metastasis of
differentiated thyroid carcinoma: Treatment results in 101 patients. J Clin
Endocrinol Metab 60:376-380, 1985.
8. Samaan NA, Schultz PN, Hickey RC, et al: The results of various modalities
of treatment of well-differentiated thyroid carcinoma: A retrospective review of
1,599 patients. J Clin Endocrinol Metab 75:714-720, 1992.
9. Clark OH: Surgical management of follicular cancer, in Wartofsky L (ed):
Thyroid Cancer: A Comprehensive Guide to Clinical Management, pp 297-300. Totowa,
NJ, Humana Press, 2000.
10. Emerick GT, Duh QY, Siperstein AE, et al: Diagnosis, treatment, and
outcome of follicular thyroid carcinoma. Cancer 72:3287-3295 (see comment),
11. Hedinger C: Histologic Typing of Thyroid Tumors. Berlin, Springer-Verlag,
12. Nishiyama RH, Ludwig GK, Thompson NW: The prevalence of small papillary
thyroid carcinomas in 100 consecutive necropsies in an American population, in
DeGroot LJ, Frohman LA, Kaplan EL, et al (eds): Radiation-Associated Thyroid
Carcinoma, p 123. New York, Grune & Stratton, 1977.
13. Cady B: Papillary carcinoma of the thyroid gland: Treatment based on risk
group definition. Surg Oncol Clin N Am 7:633-644, 1998.
14. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am
15. McConahey WM, Hay ID, Woolner LB, et al: Papillary thyroid cancer treated
at the Mayo Clinic 1946 through 1970: Initial manifestations, pathologic
findings, therapy, and outcome. Mayo Clin Proc 61:978-996, 1986.
16. Harness JK, Fung L, Thompson NW, et al: Total thyroidectomy:
Complications and technique. World J Surg 10:781-786, 1986.
17. Bentram DA, Rademaker A, Angelos P: Evaluation of serum calcium levels in
predicting hypoparathyroidism after total/near-total thyroidectomy or
parathyroidectomy. Am Surg 67:1-4, 2001.
18. Clark OH, Duh QY: Thyroid cancer. Med Clin North Am 75:211, 1991.
19. DeGroot LJ, Kaplan EL, Shukla MS, et al: Morbidity and mortality of
follicular thyroid carcinoma. J Clin Endocrinol Metab 80:2946, 1995.
20. Thompson NW: Total thyroidectomy in the treatment of thyroid carcinoma,
in Thompson NW, Vinik AI (eds): Endocrine Surgery Update, pp 71-84. New York,
Grune & Stratton, 1983.
21. Reeve TS, Delbridge L, Brady P, et al: Secondary thyroidectomy: A 20-year
experience. World J Surg 12:449, 1988.
22. Levin KE, Clark OH, Duh QY, et al: Reoperative thyroid surgery. Surgery
111: 604, 1992.
23. Edmonds CJ, Hayes S, Kermode JC, et al: Measurement of serum TSH and
thyroid hormones in the management of treatment of thyroid carcinoma with
radioioding. Br J Radiol 50:799, 1977.
24. Maruca J, Sanatner S, Miller K, et al: Prolonged iodine clearance with a
depletion regimen for thyroid carcinoma: Concise communication. J Nucl Med
25. Rawson RW, Rall JE, Peacock W: Limitations and indications in the
treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol
26. Park HM, Perkins OW, Edmondson JW, et al: Influence of diagnostic
radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49, 1994.
27. Jeevanram RK, Shah DH, Sharma M, et al: Influence of initial large dose
on subsequent uptake of therapeutic radioiodine in thyroid cancer patient. Nucl
Med Biol 13:277, 1986.
28. Braverman LE, Pratt BM, Ebner S, et al: Recombinant human thyrotropin
stimulates thyroid function and radioactive iodine uptake in the rhesus monkey.
J Clin Endocrinol Metab 74:1135, 1992.
29. Meier CA, Braverman LE, Ebner SA, et al: Diagnostic use of recombinant
human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin
Endocrinol Metab 78:188, 1994.
30. Pacini F, Lippi F, Formica N, et al: Therapeutic doses of iodine-131
reveal undiagnosed metastases in thyroid cancer patients with detectable serum
thyroglobulin levels. J Nucl Med 28:1888, 1987.
31. Clark OH, Hoelting T: Management of patients with differentiated thyroid
cancer who have positive serum thyroglobulin levels and negative radioiodine
scans. Thyroid 4:501, 1994.
32. Grunwald F, Menzel C, Bender H, et al: Comparison of 18 FDG-PET with 131
Iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Thyroid 7:327-335, 1997.
33. Grunwald F, Pakos R, Bender H, et al: Redifferentiation therapy with
retinoic acid in follicular thyroid cancer. J Nucl Med 39:1555-1558, 1998.
34. Grunwald F, Menzel C, Bender H, et al: Redifferentiation therapy-induced
radioiodine uptake in thyroid cancer. J Nucl Med 39:1903-1906, 1998.
35. Tsang RW, Brierley JD, Simpson WJ, et al: The effects of surgery,
radioiodine, and external radiation therapy on the clinical outcome of patients
with differentiated thyroid carcinoma. Cancer 82:375-388, 1998.
36. Samuel AM, Sharma SM: Differentiated thyroid carcinomas in children and
adolescents. Cancer 67:2186-2190, 1991.
37. Harness JK, Thompson NW, McLeod MK, et al: Differentiated thyroid
carcinoma in children and adolescents. World J Surg 16:47-54, 1992.
38. Stael AP, Plukker JT, Piers DA, et al: Total thyroidectomy in the
treatment of thyroid carcinoma in childhood. Br J Surg 82:1083-1085, 1995.
39. Welch-Dinauer CA, Tuttle RM, Robie DK, et al: Clinical features
associated with metastasis and recurrence of differentiated thyroid cancer in
children, adolescents, and young adults. Clin Endocrinol 49:619-628, 1998.
40. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and
medical therapy on papillary and follicular thyroid cancer (published erratum
appears in Am J Med 98:215, 1995). Am J Med 97:418-428 (see comments), 1994.
41. Jossart GH, Clark OH: Well-differentiated thyroid cancer. Curr Probl Surg
42. Cady B, Rossi R: An expanded view of risk-group definition in
differentiated thyroid carcinoma. Surgery 104:947-953, 1988.
43. Hay ID, Grant CS, Taylor WF, et al: Ipsilateral lobectomy vs bilateral
lobar resection in papillary thyroid carcinoma: A retrospective analysis of
surgical outcome using a novel prognostic scoring system. Surgery 102:1088-1095,
44. Grant CS, Hay ID, Gough IR, et al: Local recurrence in papillary thyroid
carcinoma: Is extent of surgical resection important? Surgery 104:954-962, 1988.
45. Hay ID, Bergstralh EJ, Goellner JR, et al: Predicting outcome in
papillary thyroid carcinoma: Development of a reliable prognostic scoring system
in a cohort of 1,779 patients surgically treated at one institution during 1940
through 1989. Surgery 114:1050-1058, 1993.